Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Omthera Pharmaceuticals gets $17.6mm through the sale of debt

Executive Summary

Cardiovascular therapeutics firm Omthera Pharmaceuticals Inc. has raised $17.6mm through the sale of debt and other securities to 13 undisclosed investors. The company is developing Phase III Epanova for dyslipidemia.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement
    • Convertible Debt

Related Companies

Advertisement
UsernamePublicRestriction

Register